The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.
Analysis & Context
The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development. Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says. Stay informed with the latest developments and expert analysis on this important story.
The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.